Electronegative low-density lipoprotein

Current Opinion in Lipidology

Volumn 15, Issue 3, 2004, Pages 329-335

  Sánchez Quesada, José Luis ^a   Benítez, Sonia ^a   Ordóñez Llanos, Jordi ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Electronegative LDL; Endothelial cells; Inflammation; Oxidation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; ATHEROGENESIS; CELL CULTURE; CYTOKINE PRODUCTION; DNA SYNTHESIS; ELECTRICAL PARAMETERS; ENDOTHELIUM CELL; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; ELECTRICITY; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; INFLAMMATION; INTERLEUKIN-8; LIPOPROTEINS, LDL; RISK; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 2642515006     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200406000-00014     Document Type: Review

References (56)

1. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 1996; 16:831-842.
2. Kovanen PT, Pentikäinen MO. Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis. Curr Opin Lipidol 2003; 14:411-419. In an editorial comment the authors review the pros and cons regarding the possibility that LDL modification occurs in the circulation, rendering bioactive lipoproteins.
3. Holvoet P, Vanhaecke J, Janssens J, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98:1487-1494.
4. Ehara S, Ueda M, Nakuro T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103:1955-1960.
5. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002; 22:1649-1654.
6. Schuh J, Fairclough GF, Haschemeyer RH. Oxygen-mediated heterogeneity of apo-low-density lipoprotein. Proc Natl Acad Sci U S A 1978; 75:3173-3177.
7. Kim HJ, Kurup IV. Nonenzymatic glycosylation of human low density lipoprotein: evidence for in vivo and in vitro glucosylation. Metabolism 1982; 31:348-352.
8. Orekhov AN, Tertov VV, Mukhin DN, Mikhailenko IA. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem Biophys Res Commun 1989; 162:206-211.
9. Avogaro P, Bittolo-Bon G, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis 1988; 8:79-87.
10. Cazzolato G, Avogaro P, Bittolo-Bon G. Characterization of a more electronegatively-charged LDL subfraction by ion exchange HPLC. Free Rad Biol Med 1991; 11:247-253.
11. Avogaro P, Cazzolatto G, Bittolo-Bon G. Some questions concerning a small, more electronegative LDL circulating in human plasma. Atherosclerosis 1991; 91:163-171.
12. Hodis HN, Kramsch DM, Avogaro P, et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low-density lipoprotein (electronegative LDL). J Lipid Res 1994; 35:669-677.
13. Sevanian A, Hwang J, Hodis H, et al. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 1996; 16:784-793.
14. Sevanian A, Bittolo-Bon G, Cazzolato G, et al. Electronegative LDL is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res 1997; 38:419-428.
15. Tertov W, Bittolo-Bon G, Sobenin IA, et al. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol 1995; 62:166-172.
16. Shimano H, Yamada N, Ishibashi S, et al. Oxidation-labile subfraction of human plasma low-density lipoprotein isolated by ion-exchange chromatography. J Lipid Res 1991; 32:763-773.
17. Chappey B, Myara I, Benoit MO, et al. Characteristics often charge-differing subfractions isolated from human native low-density lipoprotein (LDL): no evidence of peroxidative modifications. Biochim Biophys Acta 1995; 1259:261-270.
18. Demuth K, Myara I, Chappey B, et al. A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol 1996; 16:773-783.
19. Nyyssönen K, Kaikkonen J, Salonen JT. Characterization and determinants of an electronegatively-charged low-density lipoprotein in human plasma. Scand J Clin Lab Invest 1996; 56:681-689.
20. de Castellarnau C, Sánchez-Quesada JL, Benítez S, et al. Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20:2281-2287.
21. Sánchez-Quesada JL, Camacho M, Antón R, et al. Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 2003; 166:261-270. LDL(-) from familial hypercholesterolemia patients shows a similar proinflammatory effect to LDL(-) from normolipemic patients. The authors found no evidence of lipoperoxidative modification in LDL(-).
22. Holvoet P, Perez G, Zhao Z, et al. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995; 95:2611-2619.
23. Greilberger J, Wang X, Ledinski G, et al. Presence of aldehydic epitopes on a minor low density lipoprotein fraction. Free Rad Biol Med 1999; 26:1489-1494.
24. Bittolo-Bon G, Cazzolato G, Avogaro P. Probucol protects low-density lipoproteins from in vitro and in vivo oxidation. Pharmacol Res 1994; 29:337-344.
25. Vedie B, Jeunemaitre X, Mégnien JL, et al. Charge heterogeneity of LDL in asymptomatic hypercholesterolemic men is related to lipid parameters and variations in the apoB and CIII genes. Arterioscler Thromb Vasc Biol 1998; 18:1780-1789.
26. Sánchez-Quesada JL, Otal-Entraigas C, Franco M, et al. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with familial hypercholesterolemia. Am J Cardiol 1999; 84:655-659.
27. Sánchez-Quesada JL, Benítez S, Franco M, et al. Density distribution of electronegative LDL (LDL(-)) in normolipemic and hyperlipemic subjects. J Lipid Res 2002; 43:699-705.
28. Sánchez-Quesada JL, Pérez A, Caixàs A, et al. Electronegative low-density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control. Diabetologia 1996; 39:1469-1476.
29. Sánchez-Quesada JL, Pérez A, Caixàs A, et al. Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. J Clin Endocrinol Metab 2001; 86:3243-3249.
30. Moro E, Zambón C, Pianetti S, et al. Electronegative low density lipoprotein subform is increased in type 2 (non-insulin-dependent) microalbuminuric patients and is closely associated with LDL susceptibility to oxidation. Acta Diabetol 1998; 35:161-164.
31. Moro E, Alessandrini P, Zambón C, et al. Is glycation of low density lipoproteins in patients with type 2 diabetes mellitus an LDL pre-oxidative condition? Diabet Med 1999; 16:663-669.
32. Ziouzenkova O, Asatryan L, Akmal M, et al. Oxidative cross-linking of apoB100 and hemoglobin results in low density lipoprotein modification in blood. J Biol Chem 1999; 27:18916-18924.
33. Tomasik A, Jache W, Skrzep-Poloczek B, et al. Circulating electronegatively-charged low-density lipoprotein in patients with angiographically documented coronary artery disease. Scand J Clin Lab Med 2003; 63:259-266.
34. Benítez S, Ordóñez-Llanos J, Franco M, et al. Effect of simvastatin in familial hypercholesterolemia on the affinity of charge-differing low-density lipoprotein subfractions to the low-density lipoprotein receptor. Am J Cardiol; 2004; 93:414-420.
35. -. Free Rad Biol Med 1999; 31:82-89.
36. Asatryan L, Ziouzenkova O, Duncan R, Sevanian A. Heme and lipid peroxides in hemoglobin-modified low-density lipoprotein mediate cell survival and adaptation to oxidative stress. Blood 2003; 102:1732-1739. The authors found that heme and lipid peroxides in hemoglobin-modified LDL induce an adaptative response against cell death. Hemoglobin-modified LDL shares some characteristics with plasma LDL(-) but is not cytotoxic to vascular cells and, in contrast, improves cell survival.
37. Benítez S, Sánchez-Quesada JL, Lucero L, et al. Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are related to the increase in associated non-esterified fatty acids. Atherosclerosis 2002; 160:223-232.
38. Kleinman Y, Krul ES, Burnes M, et al. Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB100 epitopes and the interaction of LDL with cells. J Lipid Res 1988; 29:729-743.
39. Klouche M, Dorweiler M, Kirchmann R, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182:1959-1971.
40. Benítez S, Sánchez-Quesada JL, Ribas V, et al. Platelet-activating factor acetylhydrolase is mainly associated with electronegative LDL subfraction. Circulation 2003; 108:92-96. The observation that PAF-AH binds preferentially with LDL(-) suggests that the inflammatory action of LDL(-) could be related to this enzyme. Since PAF-AH acts on oxidized phospholipids, at least a low degree of lipoperoxidation should be present in LDL(-). This finding adds further controversy as to whether or not PAF-AH is a pro- or antiinflammatory enzyme.
41. LaBelle M, Blanche PJ, Krauss RM. Charge properties of low density lipoprotein subclasses. J Lipid Res 1997; 38:690-700.
42. Sevanian A, Hodis HN, Hwang J, et al. Characterization of endothelial cell injury by cholesterol oxidation products found in oxidized LDL. J Lipid Res 1995; 36:1971-1986.
43. Chang YH, Abdalla DSP, Sevanian A. Characterization of cholesterol oxidation products formed by oxidative modification of low density lipoprotein. Free Rad Biol Med 1997; 23:202-214.
44. Chen CH, Jiang T, Yang JH, et al. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation 2003; 107:2102-2108. A novel mechanism for LDL(-)-induced endothelial cell death is proposed. The most electronegative fraction of LDL from familial hypercholesterolemia patients (named FH-L5) suppresses fibroblast growth factor 2 transcription, resulting in increased apoptosis. PAF-like lipids are suggested to be involved in this apoptotic process. However, the authors failed to isolate an electronegative LDL fraction with the same characteristics as FH-L5 from normolipemic individuals.
45. Yang CY, Raya JL, Chen HH, et al. Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol 2003; 23:1083-1090. The authors succeeded in isolating L5 from normolipemic individuals (N-L5) although in a proportion fourfold lower than FH-L5. However, whereas FH-L5 shows evidence of oxidative modification N-L5 appears as a nonoxidized LDL subfraction. Moreover, FH-L5, but not N-L5, induced endothelial cell-monocyte adhesion, changes in endothelial cell morphology and decreased DNA synthesis and fibroblast growth factor 2 production.
46. Vedie B, Myara I, Pech MA, et al. Fractionation of charge-modified low density lipoproteins by fast protein liquid chromatography. J Lipid Res 1991; 32:1359-1369.
47. Ziouzenkova O, Asatryan L, Sahady D, et al. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem 2003; 278:39874-39881. This paper reports that LDL(-) increases tumor necrosis factor α-induced expression of vascular cell adhesion molecule, a process mediated by NF-κB and activating protein 1. This effect is reversed by lipolysis of LDL(-) by lipoprotein lipase. Lipoprotein lipase-treated LDL(-) releases hydroxy-octadecadienoic acids, potent PPARα activators which, in turn, suppress NF-κB and activating protein 1 activation. These findings suggest putative mechanisms that may limit inflammatory responses to LDL(-).
48. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003; 23:853-858.
49. Lam TK, Carpentier A, Lewis GF, et al. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003; 284:E863-E873.
50. 2 in vascular disease. Circ Res 2001; 89:298-304.
51. Suriyaphol P, Fenske D, Zähringer U, et al. Enzymatically modified non-oxidized low-density lipoprotein induces interleukin-8 in human endothelial cells: role of free fatty acids. Circulation 2002; 106:2581-2587.
52. 2 treatment generates lysophosphatidylcholine which induces MCP-1 production in cultured endothelial cells through the activation of NF-κB. This effect was prevented by a nitric oxide donor.
53. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem 1997; 272:17895-17898.
54. Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338:479-487.
55. Tsimihodimos V, Karabina SAP, Tambaki AP, et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002; 43:256-263.
56. Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 2001; 1:121-125.